



(Use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 6 |
|-------|---|----|---|

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/622,928 |
| Filing Date | July 18, 2003 |
| First Named Inventor | S. Banerjee |
| Art Unit | 1641 |
| Examiner Name | David J. Blanchard |
| Attorney Docket Number | BBC-203 |

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /David Blanchard/ | Date Considered | 09/01/2006 |
|-----------------------|-------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/622,928 |
| Filing Date | July 18, 2003 |
| First Named Inventor | S. Banerjee |
| Art Unit | 1641 |
| Examiner Name | David J. Blanchard |
| Attorney Docket Number | BBC-203 |

Sheet 2 of 6

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| DB | | BAEDER et al, "Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice", Clin Exp Immunol (1992)89, 174-178 | |
| | | BAILEY et al, "Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice", Int. J. Obesity (1982)6, 11-21 | |
| | | BARBIERI et al, "Is Chronic Inflammation a Determinant of Blood Pressure in the Elderly?", Am J. Hypertens (2003 Jul)16(7), 537-543 | |
| | | BENJAFIELD et al, "TNFRSF1B in Genetic Predisposition to Clinical Neuropathy and Effect on HDL Cholesterol and Glycosylated Hemoglobin in Type 2 Diabetes", Diabetes Care (2001 Apr) 24(4), 753-757 | |
| | | BLUHER et al, "Plasma Levels of Tumor Necrosis Factor-alpha, Angiotensin II, Growth Hormone, and IGF-I Are not Elevated in Insulin-Resistant Obese Individuals with Impaired Glucose Tolerance", Diabetes Care (2001 Feb)24(2), 328-334 | |
| | | BRAY & YORK, "Genetically Transmitted Obesity in Rodents", Physiological Reviews, (1971) 51, 598-646 | |
| | | CHU et al, "Glycemic status and soluble tumor necrosis factor receptor levels in relation to plasma leptin concentrations among normal weight and overweight US men" Int J Obes (2000) 24, 1085-1092 | |
| | | CLAUSELL et al, "Increased Expression of Tumor Necrosis Factor-alpha in Diabetic Macrovasculopathy", Cardiovasc Pathol, (1999 May/June)8(3), 145-151 | |
| | | COLEMAN, "Obese and Diabetes: Two Mutant Genes Causing Diabetes-Obesity Syndromes in Mice", Diabetologia (1978)14, 141-148 | |
| DB | | DAIMON M, et al, "Decreased Serum Levels of Andiponectin Are a Risk Factor for the Progression to Type 2 Diabetes in the Japanese Population", Diabetes Care (2003 Jul) 26(7), 2015-2020 | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /David Blanchard/ | Date Considered | 09/01/2006 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | |
|---|---|--------------------------|--------------------|------------------------|---------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/622,928 | | |
| | | Filing Date | July 18, 2003 | | |
| | | First Named Inventor | S. Banerjee | | |
| | | Art Unit | 1641 | | |
| | | Examiner Name | David J. Blanchard | | |
| Sheet | 3 | of | 6 | Attorney Docket Number | BBC-203 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| DB | | DEVARAJ et al, "Low -Density Lipoprotein Postsecretory Modification, Monocyte Function, and Circulating Adhesion Molecules in Type 2 Diabetic Patients With and Without Macrovascular Complications", Circulation (2000 Jul 11), 102(2), 191-196 | |
| | | GRUNDY & BARNETT, "Metabolic and Health Complications of Obesity" Dis. Mon. (1990) 36, 645-731. | |
| | | HAMADA et al, "Insulin Secretion to Glucose as Well as Nonglucose Stimuli Is Impaired in Spontaneously Diabetic Nagoya-Shibata-Yasuda Mice", Metabolism (2001)50, 1282-1285 | |
| | | HASEYAMA et al, "Complications of IgA Nephropathy in a Non-Insulin-Dependent Diabetes Model, the Akita Mouse", Tohoku J Exp Med (2002)198, 233-244 | |
| | | HATTORI et al, "High-glucose-induced nuclear factor kB activation in vascular smooth muscle cells", Cardiovasc Res. (2000)46, 188 | |
| | | HOTAMISLIGIL et al, "Increased Adipose Tissue Expression of Tumor Necrosis Factor-alpha in Human Obesity and Insulin Resistance", J. Clinl Invest (1995)95, 2409-2415 | |
| | | HOTAMISLIGIL GS et al, "Adipose Expression of Tumor Necrosis Factor-alpha: Direct Role in Obesity-Linked Insulin Resistance", Science (1993 Jan 1)259, 87-91 | |
| | | ISHII et al, "Tumor Necrosis Factor Alpha Gene G-308A Polymorphism, Insulin Resistance, and Fasting Plasma glucose in Young, Older, and Diabetic Japanese Men", Metabolism (2000 Dec) 49(12), 1616-1618 | |
| | | KATSUKI et al, "Serum Levels of Tumor Necrosis Factor-alpha Are Increased in Obese Patients with Noninsulin-Dependent Diabetes Mellitus", J Clin Endocrinol Metab (1998 Mar)83(3), 859-862 | |
| DB | | KOLB, "Mouse Models of Insulin Dependent Diabetes: Low-Dose Streptozocin-Induced Diabetes and Nonobese Diabetic (NOD) Mice", Diabetes/Metab Rev (1987)3, 751-778 | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /David Blanchard/ | Date Considered | 09/01/2006 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | |
|---|---|--------------------------|--------------------|------------------------|---------|
| Substitute for form 1449/PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/622,928 | | |
| | | Filing Date | July 18, 2003 | | |
| | | First Named Inventor | S. Banerjee | | |
| | | Art Unit | 1641 | | |
| | | Examiner Name | David J. Blanchard | | |
| Sheet | 4 | of | 6 | Attorney Docket Number | BBC-203 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| DB | | LECHLEITNER et al, "Tumour necrosis factor-alpha plasma levels in elderly patients with Type 2 diabetes mellitus-observations over 2 years" Diabetes Med (2002) 19 (11), 949-953 | |
| | | LEE et al, "TNF and TNF Receptor Polymorphisms in Korean Behcet's Disease Patients", Human Immunol (2003)64(6), 614-620 | |
| | | MAKINO et al, "Breeding of a Non-Obese, Diabetic Strain of Mice", Exp Anim (1980)29, 1-13 | |
| | | MCCALL et al, "Serum tumour necrosis factor alpha and insulin resistance in gastrointestinal cancer" Br. J. Surg (1992 Dec)79(12), 1361-1363 | |
| | | MISHIMA et al, "Relationship between serum tumor necrosis factor-alpha and insulin resistance in Obese men with Type 2 diabetes mellitus" Diabetes Res Clin Pract (2001) 52(2), 119-123 | |
| | | MULLER et al, "Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors", Diabetologia (2002) 45, 805-812 | |
| | | NAVARRO et al, "Inflammatory Parameters Are Independently Associated With Urinary Albumin in Type 2 Diabetes Mellitus", Am J Kidney Dis (2003 Jul)42(1), 53-61 | |
| | | NISHINA et al, "Atherosclerosis in Genetically Obese Mice: The Mutants Obese, Diabetes, Fat, Tubby, and Lethal Yellow" Metab (1994)43, 554-558 | |
| | | OLD, L., "Tumor Necrosis Factor (TNF)", Science (1985)230, 630-632 | |
| DB | | PFEIFFER, et al, "Circulating Tumor Necrosis Factor alpha is Elevated in Male but Not in Female Patients With Type II Diabetes Mellitus", Horm Metab Res (1997)29, 111-114 | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /David Blanchard/ | Date Considered | 09/01/2006 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/622,928 |
| Filing Date | July 18, 2003 |
| First Named Inventor | S. Banerjee |
| Art Unit | 1641 |
| Examiner Name | David J. Blanchard |
| Attorney Docket Number | BBC-203 |

Sheet 5 of 6

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| DB | | PIHLAJAMAKI et al, "The Effect of the-308A Allele of the TNF-alpha Gene on Insulin Action Is Dependent on Obesity", Obes Res (2003 Jul)11(7), 912-917 | |
| | | QIANG et al, "Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats", Diabetologia (1998)41, 1321-1326 | |
| | | SCHOLZ et al, "Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence", Trends Microbiol (2003)11, 171-178 | |
| | | SPIEGELMAN et al, "Through Thick and Thin: Wasting, Obesity, and TNFalpha", Cell (1993 May 21)73(4), 625-627 | |
| | | TSUDA et al, "Dietary Cyanidin 3-O-beta-D-Glucoside-Rich Purple Corn Color Prevents Obesity and Ameliorates Hyperglycemia in Mice", J Nutr (2003 Jul) 33(7), 2125-2130 | |
| | | UEDA et al, "Genetic Analysis of Late-Onset Type 2 Diabetes in a Mouse Model of Human Complex Trait", Diabetes (1999 May)48, 1168-1174 | |
| | | VENN et al, "Elevated Synovial Fluid Levels of Interleukin-6 and Tumor Necrosis Factor Associated with Early Experimental Canine Osteoarthritis", Arthritis Rheum (1993) 36, 819-826 | |
| | | WESTACOTT et al, "Tumor Necrosis Factor-alpha Receptor Expression on Chondrocytes Isolated from Human Articular Cartilage", J Rheumatol (1994 Sep)1(9), 1710-1715 | |
| ✓ | | WESTMAN, "Development of the Obese-Hyperglycaemic Syndrome in Mice", Diabetologia (1968)4, 141-149 | |
| DB | | ZHANG et al, "Tumor Necrosis Factor Expression in Arterial Walls of Diabetic Rats", J Tongji Med Univ (1999)19, 203-205 | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /David Blanchard/ | Date Considered | 09/01/2006 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | |
|---|---|--------------------------|--------------------|------------------------|---------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/622,928 | | |
| | | Filing Date | July 18, 2003 | | |
| | | First Named Inventor | S. Banerjee | | |
| | | Art Unit | 1641 | | |
| | | Examiner Name | David J. Blanchard | | |
| Sheet | 6 | of | 6 | Attorney Docket Number | BBC-203 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|---------------------------|---|----------------|
| Examiner Initials* | Cite. No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| DB | | ZINMAN et al, "Circulating Tumor Necrosis Factor-alpha Concentrations in a Native Canadian Population with High Rates of Type 2 Diabetes Mellitus", J Clin Endocrinol Metab (1999 Jan) 4(1),272-278 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /David Blanchard/ | Date Considered | 09/01/2006 |
|-----------------------|-------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.